GlassScriptPhysician profile
James M Trice
NPI 1427062983
$1,784.80
in general payments reported to CMS, 2019-2025
18 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $23.35 · 2021: $43.32 · 2022: $187 · 2023: $233 · 2024: $680 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,339.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $354.81 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $207.55 | 2023-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $202.37 | 2024-2025 | |
| Saluda Medical Americas, INC. | $153.11 | 2024 | Evoke |
| Idorsia Pharmaceuticals US INC | $148.84 | 2023-2024 | Quviviq |
| Heartflow, INC. | $136.49 | 2023-2025 | Ffrct |
| Horizon Therapeutics Plc | $118.65 | 2019 | |
| Boston Scientific Corporation | $112.72 | 2024-2025 | Watchman Flx |
| American Regent | $84.69 | 2024 | Injectafer |
| Amgen INC. | $54.40 | 2024-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $41.90 | 2019-2021 | |
| Viiv Healthcare Company | $31.08 | 2022 | |
| Esperion Therapeutics, INC. | $28.13 | 2022 | |
| Exact Sciences Corporation | $26.84 | 2025 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $23.35 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $23.10 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Endo Pharmaceuticals INC. | $18.75 | 2019 | |
| Glaxosmithkline, LLC. | $18.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Trice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.